VRTX - Vertex Pharmaceuticals Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
156.98
+0.70 (+0.45%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close156.28
Open155.50
Bid0.00 x 1200
Ask0.00 x 1000
Day's Range155.31 - 157.32
52 Week Range117.38 - 178.15
Volume646,398
Avg. Volume1,509,398
Market Cap40.003B
Beta1.94
PE Ratio (TTM)151.09
EPS (TTM)1.04
Earnings DateJul 24, 2018 - Jul 30, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est192.00
Trade prices are not sourced from all markets
  • Tesaro Stock: What’s the Upside Potential?
    Market Realist2 days ago

    Tesaro Stock: What’s the Upside Potential?

    Tesaro (TSRO) is a commercial stage biopharmaceutical company focused on developing treatments for solid tumors. Tesaro is licensed and developing a number of oncology-related product candidates. Of the 19 analysts covering Tesaro in May, 12 analysts gave the stock a “buy” or higher rating, while seven analysts gave a “hold” rating.

  • Gauging the Upside Potential of Vertex Pharmaceuticals Stock
    Market Realist2 days ago

    Gauging the Upside Potential of Vertex Pharmaceuticals Stock

    Vertex Pharmaceuticals (VRTX) is focused on developing and bringing to market therapies for treating cystic fibrosis (or CF) and advancing research and development programs for other diseases. Of the 25 analysts covering Vertex Pharmaceuticals in May, 21 of them have given the stock a “buy” or higher rating, and four have given it a “hold.” The mean rating for the stock is 1.76 with a target price of $191.39, implying an upside of 22.6% over its closing price of $156.16 on May 16. Of the 26 analysts covering Gilead Sciences (GILD) in May, 16 of them have given the stock a “buy” or higher rating, and ten have given it a “hold.” The mean rating for the stock is 2.15 with a target price of $85.81.

  • Vertex Pharmaceuticals: Drugs That Are Making It Happen
    Market Realist2 days ago

    Vertex Pharmaceuticals: Drugs That Are Making It Happen

    Vertex Pharmaceuticals’ (VRTX) Kalydeco generated sales of $249.5 million in the first quarter, up from $185.7 million YoY (year-over-year). The drug is targeted to treat cystic fibrosis patients with G551D mutation in the CFTR gene. The increase was due to additional patients being treated with Kalydeco after Vertex completed reimbursement discussions in non-US jurisdictions and due to an increase in the number of eligible patients to receive Kalydeco through label expansion.

  • What Led to MEI Pharma Stock’s 55% Rise Last Week?
    Market Realist2 days ago

    What Led to MEI Pharma Stock’s 55% Rise Last Week?

    MEI Pharma (MEIP) saw a 55% rise in its stock price between May 11 and May 18. On May 18, the stock closed at $3.46, a 119% increase from its 52-week low of $1.58 on May 19, 2017. On May 15, 2018, MEI Pharma stock closed at $3.40, a ~34.4% increase over the previous close of $2.53 on May 14, 2018. The stock rose ~58% in the last quarter. 

  • Why Wall Street Analysts Are Mostly Positive on CRISPR
    Market Realist5 days ago

    Why Wall Street Analysts Are Mostly Positive on CRISPR

    In December 2017, CRISPR Therapeutics (CRSP) entered a collaboration with Vertex Pharmaceuticals (VRTX) for the co-development and co-commercialization of CTX001. CRISPR Therapeutics submitted a CTA (clinical trial application) for CTX001 for the initiation of phase 1/2 trial for the evaluation of the safety and efficacy in the treatment of beta-thalassemia in Europe. CRISPR Therapeutics plans to submit an Investigational New Drug application to the FDA for the approval of an initiation of phase 1/2 clinical trial in the US for the treatment of sickle cell disease in the second half of 2018.

  • The Zacks Analyst Blog Highlights: General Dynamics, Enbridge, CSX, Humana and Vertex
    Zacks8 days ago

    The Zacks Analyst Blog Highlights: General Dynamics, Enbridge, CSX, Humana and Vertex

    The Zacks Analyst Blog Highlights: General Dynamics, Enbridge, CSX, Humana and Vertex

  • How Did Jazz Pharmaceuticals Perform in 1Q18?
    Market Realist14 days ago

    How Did Jazz Pharmaceuticals Perform in 1Q18?

    In 1Q18, Jazz Pharmaceuticals (JAZZ) generated revenue of $444.6 million compared to $376.1 million in 1Q17, which reflected an ~18% rise on a YoY (year-over-year) basis and a ~2% rise quarter-over-quarter.

  • GlobeNewswire14 days ago

    Factors of Influence in 2018, Key Indicators and Opportunity within American Homes 4 Rent, Discovery Communications, Vertex Pharmaceuticals, The New York Times, Palatin Technologies, and E*TRADE Financial — New Research Emphasizes Economic Growth

    NEW YORK, May 10, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of American ...

  • 3 Top Biotech Stocks to Buy in May
    Motley Fool15 days ago

    3 Top Biotech Stocks to Buy in May

    Looking for a few timely buys in the biotech space? Give these gems a closer look.

  • Here's My Top Stock to Buy in May
    Motley Fool16 days ago

    Here's My Top Stock to Buy in May

    A near monopoly and multiple paths for growth make this my favorite stock to buy right now.

  • Wall Street Recommendations for Exelixis in May 2018
    Market Realist17 days ago

    Wall Street Recommendations for Exelixis in May 2018

    As per the terms of the agreement, Exelixis and Invenra will jointly discover and develop antibodies with the help of Invenra’s B-Body technology platform, which allows high-throughput screening along with in vitro and in vivo preclinical characterization for the development of potential therapeutic candidates. According to the terms of the agreement, Exelixis will lead preclinical trials, manufacturing, the clinical development of both single-regimen and combination-regimen therapies along with regulatory filling and commercialization. Also under this collaboration, Exelixis and Invenra plan to conduct up to six discovery projects.

  • How Did Exelixis Perform in 1Q18?
    Market Realist19 days ago

    How Did Exelixis Perform in 1Q18?

    In 1Q18, Exelixis (EXEL) generated revenues of $212.3 million yesterday, compared to $80.89 million in 1Q17. In 1Q18, Exelixis witnessed ~77% growth on a quarter-over-quarter basis.

  • Biotech Stock Roundup: ALXN, VRTX Post Solid Results, GILD Disappoints in Q1
    Zacks22 days ago

    Biotech Stock Roundup: ALXN, VRTX Post Solid Results, GILD Disappoints in Q1

    The biotech sector was in focus over the last five trading sessions as several bigwigs like Gilead and Vertex, among others reported results while some others provided pipeline updates.

  • Business Wire23 days ago

    Vertex Awards $400,000 in Scholarships to People Living with Cystic Fibrosis and Their Immediate Family Members

    Vertex Pharmaceuticals Incorporated (VRTX) today announced the recipients of scholarships as part of its second All in for CF Scholarship program. Each of the 80 scholarship recipients will be awarded $5,000 for the 2018-2019 academic year. The Vertex All in for CF Scholarship program was established in 2017 to help people living with cystic fibrosis (CF) and their immediate family members pursue two-year, four-year or graduate degrees.

  • ACCESSWIRE23 days ago

    Blog Exposure - EMA Scientific Committee Recommended Granting Marketing Authorization to Gilead's Biktarvy(R) for HIV-1 Treatment

    LONDON, UK / ACCESSWIRE / May 01, 2018 / Active-Investors.com has just released a free research report on Gilead Sciences, Inc. (NASDAQ: GILD). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=GILD as the Company's latest news hit the wire.

  • Vertex Pharmaceuticals Takes a Detour Around the FDA's Roadblock
    Motley Fool23 days ago

    Vertex Pharmaceuticals Takes a Detour Around the FDA's Roadblock

    The news shouldn't distract from a solid first quarter.

  • 5 Things You'll Want to Know From Vertex Pharmaceuticals' Q1 Conference Call
    Motley Fool25 days ago

    5 Things You'll Want to Know From Vertex Pharmaceuticals' Q1 Conference Call

    What the biotech's management had to say about what's next for Vertex.

  • Analysts’ Recommendations for Vertex Pharmaceuticals
    Market Realist26 days ago

    Analysts’ Recommendations for Vertex Pharmaceuticals

    In February 2018, Vertex Pharmaceuticals (VRTX) announced the results of a Phase 2 trial for VX-150, an investigational NaV1.8 inhibitor. It had positive results in patients with acute pain after bunion removal and was well tolerated by patients.

  • Vertex Slips As FDA Delays Cystic Fibrosis Drug — But There's A Silver Lining
    Investor's Business Daily26 days ago

    Vertex Slips As FDA Delays Cystic Fibrosis Drug — But There's A Silver Lining

    Vertex slid to a three-week low Friday after the FDA required additional tests for one compound used in a potential cystic fibrosis regimen.

  • How Did Vertex Pharmaceuticals Perform in 1Q18?
    Market Realist26 days ago

    How Did Vertex Pharmaceuticals Perform in 1Q18?

    In 1Q18, Vertex Pharmaceuticals’ (VRTX) revenue rose ~33% YoY (year-over-year) to $638 million from $481 million. It grew ~3% quarter-over-quarter.

  • Vertex (VRTX) Q1 Earnings Beat on Strong CF Products Sales
    Zacks27 days ago

    Vertex (VRTX) Q1 Earnings Beat on Strong CF Products Sales

    Vertex Pharma (VRTX) first-quarter earnings increase from the year-ago period led by strong sales trend of CF drugs.

  • What Analysts Recommend for Neurocrine Biosciences in April 2018
    Market Realist27 days ago

    What Analysts Recommend for Neurocrine Biosciences in April 2018

    In April 2018, the US FDA (Food and Drug Administration) notified Neurocrine Biosciences and AbbVie (ABBV) that it would require more time to review additional information associated with the liver function tests provided by AbbVie in addition to it its NDA (new drug application) for Elagolix. The US FDA granted the new PDUFA (Prescription Drug Fee User Act) action date in 3Q18.

  • Vertex Pharma Tops Quarterly Views On Strong Cystic Fibrosis Drug Sales
    Investor's Business Daily27 days ago

    Vertex Pharma Tops Quarterly Views On Strong Cystic Fibrosis Drug Sales

    Vertex on Thursday reported adjusted profit of 76 cents per share on sales of $640.8 million for the first quarter.

  • How Neurocrine Biosciences Is Positioned ahead of 1Q18 Earnings
    Market Realist27 days ago

    How Neurocrine Biosciences Is Positioned ahead of 1Q18 Earnings

    How Neurocrine Biosciences Is Positioned ahead of 1Q18 EarningsNeurocrine Biosciences revenue trends

  • Business Wire27 days ago

    Vertex Reports First-Quarter 2018 Financial Results

    Vertex Pharmaceuticals Incorporated today reported consolidated financial results for the first quarter ended March 31, 2018 and reviewed recent progress with its approved and investigational medicines.